During regular trading hours, there were many stocks that continued to break up to the upside. These stocks are usually going up with news.If you are looking to day trade also check out my Top 2011 Stock Gainers , Stocks to Buy 2012.You can also check previous stocks to buy reports- Right Here today.Hot stocks Today Right Here.I also have technical analysis different stocks-Right Here. Market Technical analysis Right Here
Quick Look Market Closing Price:
At the close: Dow +0.34% to 12948. S&P +0.23% to 1361. Nasdaq -0.27% to 2951.
Treasurys: 30-year -0.15%. 10-yr -0.06%. 5-yr -0.01%.
Commodities: Crude +1.24% to $103.92. Gold -0.24% to $1724.25.
Currencies: Euro +0.14% vs. dollar. Yen +0.79%. Pound -0.23%.
After Hours News:
Corcept Therapeutics (CORT), a specialty drug company that hasn’t generated revenue since 2009, wins FDA approval for its Korlym treatment that uses the active ingredient of the abortion pill RU-486 to treat Cushing’s Syndrome. Shares +42.5% after a trading halt
Blackstone (BX) has halted talks to acquire Brocade Communications (BRCD -2.2%) because the stock's price rose too high to make a leveraged buyout attractive, according to a Bloomberg report issued minutes prior to the market close. The maker of switches for data storage networks has been looking for a buyer since 2009
Codexis (CDXS) falls 12.9% AH after announcing CEO Alan Shaw has resigned to "pursue other interests." Peter Strumph, head of the company's pharmaceuticals division, will serve as interim CEO while the board searches for a full-time replacement. Codexis shares tumbled last week following the company's Q4 miss.
Blackstone (BX) has halted talks to acquire Brocade Communications (BRCD -2.2%) because the stock's price rose too high to make a leveraged buyout attractive, according to a Bloomberg report issued minutes prior to the market close. The maker of switches for data storage networks has been looking for a buyer since 2009
Codexis (CDXS) falls 12.9% AH after announcing CEO Alan Shaw has resigned to "pursue other interests." Peter Strumph, head of the company's pharmaceuticals division, will serve as interim CEO while the board searches for a full-time replacement. Codexis shares tumbled last week following the company's Q4 miss.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/
